Drug intelligence / Profile preview

Vivagest

Development stage: Unknown
Lead developer: HM Medics
Modality: Small Molecules
Administration: Oral

Overview

Vivagest is a nutraceutical product developed by HM Medics designed to support hormonal balance, fertility optimization, and maternal health. Formulated as a triple-action hormonal precursor, it contains a combination of Omega-3 fatty acids (including docosahexaenoic acid), vitamins B9 (folic acid), B12, D3, and E, along with iodine. It is specifically intended for use during the preconception period to stimulate fertility and throughout pregnancy and breastfeeding to support fetal development and reduce the risk of miscarriages and congenital malformations. Launched in 2018, it is marketed as a supplement to meet the specific nutritional needs of women during the reproductive cycle.

Brand names: Vivagest

Beyond the preview

Go deeper on Vivagest.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Vivagest.

Explore the full profile